Scopus BioPharma Inc (SCPS)
0.0021
0.00 (0.00%)
USD |
OTCM |
May 22, 16:00
Scopus BioPharma SG&A Expense (Quarterly): 0.9359M for June 30, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 0.9359M |
| March 31, 2023 | 1.071M |
| December 31, 2022 | 1.09M |
| September 30, 2022 | 0.9813M |
| June 30, 2022 | 2.670M |
| March 31, 2022 | 4.292M |
| December 31, 2021 | 6.383M |
| September 30, 2021 | 2.682M |
| June 30, 2021 | 1.727M |
| March 31, 2021 | 1.819M |
| Date | Value |
|---|---|
| December 31, 2020 | 0.6446M |
| September 30, 2020 | 0.806M |
| June 30, 2020 | 0.7107M |
| March 31, 2020 | 0.569M |
| December 31, 2019 | 0.7803M |
| September 30, 2019 | 0.7151M |
| June 30, 2019 | 0.3384M |
| March 31, 2019 | 0.393M |
| June 30, 2018 | 0.1197M |
| March 31, 2018 | 0.09M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.3384M
Minimum
Jun 2019
6.383M
Maximum
Dec 2021
1.660M
Average
0.9813M
Median
Sep 2022
SG&A Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |
| iBio Inc | 2.722M |
| Theriva Biologics Inc | 1.933M |
| Oragenics Inc | 1.797M |